• Lunai Bioworks unit BioSymetrics signed a non-binding letter of intent with Geneial to pursue a strategic collaboration in rare neurological disorders.
• Partnership targets creation of trial-ready patient cohorts by integrating patient-led datasets across multiple registries with longitudinal clinical data.
• Companies aim to use resulting cohorts to support commercial partnerships with pharmaceutical and biotechnology groups, creating potential revenue-generating collaborations.
• Initial focus covers select rare neurodevelopmental disorders, with plans to expand program scope over time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604150910PR_NEWS_USPR_____LA34749) on April 15, 2026, and is solely responsible for the information contained therein.